Selective COX-2 inhibitors with pyrazolopyridine structure in development at Glaxo Wellcome Oct. 13, 2000
Connetics' phase III human relaxin trial for scleroderma falls short of primary endpoint Oct. 11, 2000
Boehringer Ingelheim identifies new series of cytokine-inhibitory antiinflammatory agents Oct. 10, 2000
Marine natural product shows promise for hyperproliferative and inflammatory conditions Oct. 10, 2000
RSS